Advancing the cancer care, improving better patient outcomes by challenging the current practice
Building on our commitment to advancing the field of Interventional Oncology, Boston Scientific brings extended experience supported by clinical data, on the latest cryoablation technology in its portfolio of minimally invasive therapies.
Cryoablation offers minimally invasive destruction of tumours, without the need for open surgery. The marked increase in volume of percutaneous ablations is likely due in large part to a growing body evidence demonstrating comparable oncologic outcomes with partial nephrectomy, but with decreased complications and preservation of renal function.
With targeted and minimally invasive treatments, we can improve the lives of patients suffering from cancer (renal cell carcinoma at many others) and other life-altering diseases.
Cryoablation is a minimally invasive procedure enabling to ablate benign or malignant tumours using extreme cold freezing agent administrated through specific needles.
An extremely cold freezing agent (liquid nitrogen, liquid nitrous oxide, or compressed argon gas) is administered through a thin needle called a cryoprobe in a closed-loop system, freezing and destroying the abnormal tissue.
The tissues targeted for destruction and the ice ball that grows around it during the treatment, are visualized using real-time image guidance, allowing a good approximation of the frozen tissue in the ablated area.
What are the benefits for clinicians?
Cryoablation offers clinicians several unique advantages:
- Treatment zone visibility and control
- Ability to treat multiple tumours in one session
- Ability to use ice in proximity to critical structures / vasculature
- Ability to use multiple probes to “sculpt” the shape of the iceball and ablate larger tumours
- Repeatability of the treatment
Renal Cell Carcinoma